ArticleiScience2026
Lactate as a predictive biomarker and therapeutic target in cardiopulmonary bypass-associated acute kidney injury.
Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Elevated lactate is a common metabolic perturbation following cardiopulmonary bypass (CPB). This study evaluates the clinical predictive value of lactate and explores its mechanism involving protein lactylation. Machine learning (ML) algorithms applied to multicenter intensive care databases identified preoperative lactate as a dominant predictor of CPB-acute kidney injury (AKI) risk. To validate these predictions biologically, rat CPB and cellular models were utilized. Experimental results demonstrated that CPB induces glycolytic reprogramming, lactate accumulation, and elevated pan-lysine lactylation. Inhibiting the production of lactate was associated with decreased protein lactylation, lower oxidative stress, and reduced local tissue inflammation, thereby mitigating renal injury. Collectively, our interpretable ML predictive models identify lactate as a top clinical predictor of CPB-AKI, while our experimental data establish the lactate-lactylation axis as a potential mechanistic pathway linking metabolic dysfunction to renal damage. This axis represents a candidate therapeutic target requiring further validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.